NQO1 and neoplasm: The tumor size regression at 4 mg kg–1 every five days also clearly demonstrated the efficiency of the probe in HCT116 tumor xenografts with observed continuous tumor growth in the control samples and NQO1 absent cell line xenograft and a clear tumor size reduction in the presence of NQO1 expressing tumors and probe 1 treatment.